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Abstract
Duchenne muscular dystophy (DMD) is a severe muscle wasting disease caused by mutations in the dystrophin gene. By utilizing anti-
sense oligonucleotides, splicing of the dystrophin transcript can be altered so that exons harbouring a mutation are excluded from the
mature mRNA. Although this approach has been shown to be effective to restore partially functional dystrophin protein, the level of dys-
trophin protein that is necessary to rescue a severe muscle pathology has not been addressed. As zebrafish dystrophin mutants (dmd)
resemble the severe muscle pathology of human patients, we have utilized this model to evaluate exon skipping. Novel dmd mutations
were identified to enable the design of phenotype rescue studies via morpholino administration. Correlation of induced exon-skipping
efficiency and the level of phenotype rescue suggest that relatively robust levels of exon skipping are required to achieve significant ther-
apeutic ameliorations and that pre-screening analysis of exon-skipping drugs in zebrafish may help to more accurately predict clinical
trials for therapies of DMD.
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Introduction
Mutations in the dystrophin gene can lead to two forms of muscu-
lar dystrophy. Null mutations that cause complete loss of dys-
trophin function typically result in Duchenne muscular dystophy
(DMD), a lethal disease characterized by progressive muscle wast-
ing. In-frame deletions that lead to internally deleted dystrophin
protein generally result in Becker muscular dystrophy (BMD),
which shows milder symptoms than DMD with a large variation in
clinical severity.
The finding of patients with a mild form of BMD that have in-
frame deletions of often large regions of the dystrophin gene,
together with the existence of revertant, dystrophin positive fibres in
many DMD patients [1] suggests that exclusion of exons harbour-
ing mutations can result in largely functional dystrophin protein.
Similarly, the functionality of an artificial mini-dystrophin harbour-
ing deletion of exons 18 to 58 has been reported suggesting much
of the dystrophin protein may be dispensable for its function [2].
Currently, clinical trials are underway that are based on administra-
tion of exon-skipping antisense oligonucleotides (AO) [3, 4]. In exon
skipping, AOs are employed to sterically block exon recognition
splice motifs located in the pre-mature transcript. Effective blocking
leads to faulty transcript processing that does not splice targeted
exons correctly, so that they are excluded from the mature mRNA,
resulting in a shorter, but partly to largely functional dystrophin.
Although this approach will only be useful for the treatment of a
subset of patients, it is estimated that 83% of all DMD patients
would theoretically benefit from single or double exon skipping [5].
The exon-skipping approach has shown much promise in recently
finished clinical trials [3, 4]. However, these clinical trials were lim-
ited, as the AO was only administered locally into a single muscle
and healthy volunteers could not be tested due to the possibility of
adverse affects on dystrophin function. Exon skipping has also been
performed in the mdx mouse and in the golden retriever muscular
dystrophy (GRMD) dog [6, 7], and the efficacy of exon-skipping
protocols in generating Dystrophin protein has been demonstrated
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in both these models. However, the mdx mouse does not resemble
the severity of the human condition and a systematic and statistical
evaluation of exon skipping in dogs is hampered by their inefficient
breeding and phenotypic variety [8]. Therefore, the level of
dystrophin function necessary to effect full functional rescue in the
context of a severe dystrophin-deficient pathology remains unclear.
In contrast to the most commonly used model, the mdx mouse
[9], dystrophin-deficient zebrafish, named dmd ta222a [10], closely
resemble the human condition in severity, onset and specific
symptoms [11]. The progressive increase in expression of dys-
trophin protein at non-junctional sites in zebrafish correlates well
with a number of pathological similarities between dystrophin-
deficient zebrafish and patients suffering from DMD. Dystrophin-
deficient zebrafish larvae show extensive muscle degeneration
accompanied by fibrosis, inflammatory response, activation of the
muscle stem cell compartment and greater variation in myofibre
cross-sectional areas [11]. The detection of dystrophic muscle by
reduction in birefringence [12], a light effect of the fish muscle vis-
ible under polarized light, enables efficient usage of dmd mutants
in statistically evaluated experiments. In addition, zebrafish as a
model system provide valuable advantages as its embryos develop
ex utero, are translucent, amenable for drug screening [13], highly
manipulable and genetically tractable [14], suggesting that
dystrophin-deficient zebrafish could be a clinically relevant context
in which to evaluate efficacy of therapeutic strategies.
In this study, novel dystrophin-deficient zebrafish mutants were
isolated and used to evaluate efficacy of phenotype rescue by admin-
istration of morpholinos. Exon-skipping protocols were established
that deliver a graded restoration of dystrophin levels demonstrating
that only robust levels of induced exon skipping lead to sufficient
dystrophin function capable of rescuing the dmd pathology. This
analysis therefore provides a benchmark for the level of exon skip-
ping that is required to effect clinically relevant pathological amelio-
ration in the face of a fully penetrant dystrophic phenotype.
Materials and methods
Zebrafish lines and maintenance
The dmd tm90c and dmd ta222a mutant alleles were obtained from the
Tübingen Stock Collection [12]. All mutant lines were maintained in the TU
(Tübingen) zebrafish strain. Genotyping was accomplished via PCR
followed by restriction digestion (Fig. S1). All animal experiments were
approved by MAS/2009/05.
Non-complementation screen 
and allele identification
Forty-eight males were mutagenized with N-ethyl-N-nitrosourea (ENU) as
described [15] with the alteration of using 0.004% Tricaine (Sigma-Aldrich,
St. Louis, MO, USA) during treatment. Surviving fish were out-crossed to
females. The resulting F1 generation was crossed to heterozygous
dmd ta222a/ fish and the offspring analysed for their birefringence at 3 days
after fertilization (dpf). This non-complementation approach resulted in the
identification of two novel dystrophin alleles after a survey of 243 genomes.
To stabilize their genetic background, founder animals were back-crossed to
TU over six generations before further experiments were performed. To
determine the mutation rate, DNA was isolated from all F1 males and 1704
kbp at 25 randomly chosen loci were sequenced. Identified mutations were
confirmed in independent PCR, resulting in a mutation rate of 1 mutation
every 107 kbp. Cryostat cross-sections were stained with Harris haema-
toxylin and eosin or immunostained as described [11].
Morpholino oligomer injections
Morpholino oligomers were designed and named as described [16] and
ordered from Gene Tools LLC (Philomath, OR, USA). Sequences were:
Z32A(–18  7): 5-gtttatccttaaacagacacatttg-3, Z32E(83107): 5-
ttcactttcacctcctccagcactc-3 and Z32E(133157): 5-gtgactgcaccacttc-
ctgctccac-3, targeting exon 32 as indicated by the number in brackets.
Zebrafish embryos were injected at the 1- to 2-cell stage into the yolk with
1.4 nl of morpholino solutions of different concentrations. Isogenic, unin-
jected embryos from the same clutches were analysed as controls.
RNA extraction and semi-quantitative RT-PCR
Total RNA was extracted from larvae at different stages with TriReagent
(Sigma) and dystrophin cDNA was prepared with the SuperScript III 
First-Strand-Synthesis System (Invitrogen, Carlsbad, CA, USA) using the
primer 34cDNA: 5-ccaaatcacttggcataccctcc-3. The cDNA was then sub-
jected to PCR performed with Advantage-HF 2 Polymerase Mix (Clontech,
Mountain View, CA, USA) using the primers 30For: 5-ctgaacaccactgacc-
gacatc-3 and 34Rev: 5-cttctccagttcctgctttcctt-3. Resulting amplicons
were confirmed by sequencing. To determine the relative abundance of dif-
ferent dystrophin transcripts, we performed semi-quantitative RT-PCR
using wild-type (WT) dystrophin transcript (549 bp) as internal control. For
each morpholino concentration described, the PCR was optimized to keep
the number of PCR cycles to a minimum. Proportions of different ampli-
fied dystrophin transcripts were quantified by measuring the band intensi-
ties using ImageJ (densitometry).
For statistical analysis of the correlation of morpholino effi-
ciency and the ratio of dystrophic larvae, three clutches of 80–100
eggs from independent breeding pairs were injected with the
described morpholino concentrations and 3 dpf hatched larvae
were analysed for their muscle birefringence. Two larvae per
clutch, with a dystrophic phenotype when applicable, were pooled
and used for RT-PCR based analysis of dystrophin transcripts.
Data are represented as means  S.E.M.
Results
Screen for novel dystrophin alleles
In order to examine the effectiveness of the zebrafish dmd mutant
for evaluating exon-skipping protocols of DMD patients, we
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determined its conservation in comparison to the human dys-
trophin gene. Alignment of the human (muscle specific Dp427m
isoform) and zebrafish dystrophin shows that 57% of the human
protein sequence is identical (84% conserved) to zebrafish
dystrophin. Additionally, the exon–intron structure is highly
conserved: with the exception of the first and the last exon, each
human dystrophin exon has a corresponding exon in the zebrafish
sequence and skipping of any exon induces the same frame shift
in the zebrafish and the human dystrophin transcript (Fig. S2).
Thus, the zebrafish model has the potential to examine the
functional consequence of exon skipping in the context of a highly
penetrant in vivo model of DMD.
In order to study the feasibility and characteristics of pheno-
type rescue by exon skipping, the targeted exon should not
encode for a region essential for dystrophin function.
Unfortunately, the original dmd ta222a allele that we initially charac-
terized harbours a premature stop codon in an exon encoding for
a N-terminal calponin homology domain that is believed to be
essential for actin binding [10, 17] and the only other identified
allele, sapcl100, carries a splice site mutation, which itself is unsuit-
able for testing exon-skipping protocols [18]. Thus, we sought to
generate new dystrophin alleles that would fall within exons
appropriate for the evaluation of exon skipping.
To identify novel dystrophin alleles, a non-complementation
screen based on the dmd ta222a fish was performed. Adult male
zebrafish were treated with ENU and subsequently crossed to WT
female to generate F1 founders. The F1 founders were subse-
quently crossed to heterozygous dmd ta222a/ fish. Resulting
offspring were screened for their levels of birefringence at 3 dpf.
Non-complementation of the dmd ta222a allele, indicated by a
reduction in birefringence, identified 2 novel dmd mutants. In
addition, the zebrafish mutant dmd tm90c (synonym: sapje,
saptm90c), previously identified in a large scale screen but yet to be
molecularly characterized [12], was also confirmed not to comple-
ment the dmd ta222a allele (Fig. 1A–D). Whole mount immunohis-
tochemistry with antibody against dystrophin indicated loss of
dystrophin in all three mutants and each of the mutants possessed
a similar level of phenotypic severity compared to the original (Fig.
1A’–D’). Subsequent sequencing of the genomic dystrophin cod-
ing region in the mutants and comparison with the WT sequence
led to the discovery of premature stop codons within the exons
21, 32 and 53 for the alleles named dmd pc1, dmd pc2 and
dmd tm90c, respectively (Fig. 1B”–D”). The identified mutations are
widely distributed across the repetitive spectrin repeat region of
dystrophin, which is often deleted within BMD patients and is also
largely dispensable for the functional rescue of the mdx mouse by
mini-dystrophin [2]. Thus, the mutations evident in the novel dys-
trophin alleles dmd pc1, dmd pc2 and dmd tm90c, lie within regions
suitable for exon-skipping protocols (Fig. 1E).
Dystrophin restoration in dmd homozygotes via
exon skipping
AO, designed to sterically hinder specific splicing signals, can be
employed to alter the splicing of the dystrophin pre-mRNA so that
© 2011 The Authors
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Fig. 1 Novel dmd mutants identified in a non-complementation screen. (A) Birefringence of the muscle of a 3 dpf WT larva, evoked by polarized light,
indicates an ordered array of myofilaments. (B–D) All novel dmd mutants display reduced muscle birefringence. (A’) Immunofluorescence revealed that
dystrophin (green) is present at the somite borders (arrows) in siblings, (B’–D’) but absent in the homozygous dmd mutants. (B”–D”) Genomic sequenc-
ing of the dmd mutants revealed premature stop codons within exon 21 of dmd pc1/pc1, exon 32 of dmd pc2/pc2 and exon 53 of dmd tm90c/tm90c. (E) Arrows
in the schematic diagram of zebrafish dystrophin point to the location of the premature stop codon encoded in each indicated mutant. Amino acid posi-
tions are displayed in the scale bar below; calponin-homology domains are in red, hinge domains in green and spectrin-like repeats in blue.
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the targeted exon is excluded from the mature mRNA leading to an
internally deleted, but partially to largely functional dystrophin
protein. In such an exon-skipping approach, removal of the exon
may neither disrupt the open reading frame nor remove essential
regions of the protein. The skipping of exon 32, which is mutated
in dmd pc2, satisfies these two criteria.
An phosphordiamidate morpholino oligomer, Z32A(–187),
was designed to target the 5-end of exon 32. To avoid nonspe-
cific morpholino effects at high concentrations, various concen-
trations of Z32A(–18  7) were administered. By comparison of
abnormal embryo rates versus skipping efficiency, the optimal
concentration of Z32A(–18  7) for injections was established to
be 500 M (data not shown), a concentration which induced a
slight curve in the angle of the body axis and a small delay in
development. Two days after delivery of Z32A(–18  7) into 
WT embryos, RNA was isolated and RT-PCR across exons 30–34
performed. Although RT-PCR on uninjected embryos led to
detection of only WT dystrophin transcript, RT-PCR after injection
of Z32A(–18  7) resulted in two additional transcripts: one cor-
responding to a larger transcript arising from insertion of intron
31 upstream and one corresponding to a shorter amplicon origi-
nating from simultaneous skipping of the two exons 32 and 33
(Fig. 2A and B). The latter amplicon emanates from a dystrophin
transcript with a preserved open reading frame encoding for a
shorter dystrophin protein missing 121 amino acids encoded by
exons 32 and 33. Interestingly, the proportion of the two
Z32A(–18  7)-induced transcripts in relation to all detected
dystrophin transcripts is significantly higher in dmd pc2/pc2
homozygotes (82%  0.6%) than in WT embryos (45%  0.5%;
P  0.01, n  3), suggesting that the stop mutation-containing
transcript could well undergo nonsense mediated decay (Fig. 2F).
In addition, even though the amount of the two additional
© 2011 The Authors
Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
Fig. 2 Evaluation of the efficacy of exon
skipping for phenotypic rescue of dys-
trophin-deficient zebrafish. (A) Schematic
diagram of the pre-mature dystrophin tran-
script with exons represented by boxes and
introns (not to scale) marked by arches.
The positions of the primers (34cDNA,
30For and 34Rev) used for RT-PCR are
indicated and green bars mark the position
of the morpholino targets. The sizes of
exons as well as RT-PCR amplicons are
shown in bp and the position of the dmd pc2
mutation is indicated by an asterisk. Blue
exons represent translated coding
sequence, whereas white exons are not
translated with the first stop codon repre-
sented by a red block. (B–E) Schematic 
diagrams of transcripts induced by the
indicated morpholinos with the size of the 
RT-PCR amplicons indicated. (F) Injection
of Z32A(–18  7) induces a 643 bp and a
219 bp amplicon representing dystrophin
transcripts schematically depicted in (B).
Interestingly, the proportion of induced
exon-skipped transcripts is, with high
significance, increased in 2-dpf-old
dmd pc2/pc2 homozygotes compared to WT
control embryos (82%  0.6% versus 45%
 0.5%, P  0.01, n  3) suggesting that
nonsense-mediated decay proportionally
reduced the levels of un-skipped stop
codon containing transcript. (G)
Administration of Z32E(133157) leads
to exclusion of 78 bp from the 3-end of
exon 32 and administration of Z32E(83107) induces inclusion of the intron located upstream of exon 32. Combination of these two morpholinos,
however, leads to a robust skipping of exon 32, which is still detected 21 days after administration. Again, the proportion of morpholino-induced tran-
script is significantly higher in 2-dpf-old dmd pc2/pc2 homozygotes than WT embryos (93%  2% versus 66%  3%, P  0.01, n  3). (H) Comparison
of the zebrafish cryptic splice site elicited by Z32E(133157) with the corresponding human dystrophin sequence and the human 5 splice consensus
[24]. ** indicates P  0.01.
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transcripts was declining, they could still be detected 7 days after
Z32A(–18  7) delivery (Fig. 2F).
To determine, if administration of Z32A(–18  7) leads to
expression of dystrophin protein, whole mount immunohisto-
chemistry with antibodies against dystrophin was performed.
Three days after administration of Z32A(–18  7) the proportion
of the exon 31–32 deletion transcript is 4.7%  0.5% of all
dystrophin transcripts (n  8; data are means  S.E.M.) and, in
contrast to uninjected dmd pc2/pc2 homozygotes, faint dystrophin
expression could be detected in Z32A(–18  7)-injected homozy-
gous dmd pc2/pc2 at the same stage (Fig. 2B and C).
Under polarized light the zebrafish muscle shows a birefrin-
gence effect that is caused by parallel thread-like myofibrils within
muscle fibres (Fig. 3A’). This birefringence is reduced in dys-
trophin-deficient zebrafish, as the fibre organization is lost due to
detachment and retraction of fibres [10]. Therefore, the birefrin-
gence assay was employed to survey if the restored levels of dys-
trophin are sufficient to rescue the dmd pc2 phenotype. Z32A(–18
 7)-injected homozygotes, however, demonstrate a loss of bire-
fringence that is comparable to dmd pc2/pc2 homozygotes, indicat-
ing muscle loss and lack of phenotypic rescue (Fig. 3B’ and C’). In
order to survey the phenotype with an independent method,
cross-sections of uninjected and Z32A(–18  7)-injected
dmd pc2/pc2 homozygotes larvae were stained for haematoxylin
and eosin at 7 dpf. As indicated by the depicted muscle fibrosis
and myofibre loss, the muscle of dmd pc2/pc2 homozygotes
injected with Z32A(–18  7) demonstrates a level of muscle loss
comparable to that detected in untreated dmd pc2/pc2 homozygotes
(Fig. 3B” and C”). Taken together, these results reveal that
administration of the morpholino Z32A(–18  7) leads to a low
level of exon skipping that restores a detectable level of dystrophin
protein in dmd pc2/pc2 homozygotes, but does not rescue the
dmd pc2 phenotype.
Phenotype rescue of dmd pc2/pc2 homozygotes 
via exon skipping
Given the surprising complexity of the response to the blocking of
the 3 or acceptor splice site of exon 32, additional mechanisms
were sought to increase the efficacy of in-frame skipping of exon
32 in dmdpc2/pc2 homozygous mutants. In addition to blocking 
3 acceptor or 5 donor-splice sites, targeting exonic splice
enhancers (ESE) located within exons has also reported to lead to
exon-skipping events [19]. Therefore, the program “RESCUE-ESE”
was used to predict ESE located in exon 32 of dystrophin. Based
on the prediction, the morpholino Z32E(133157) was
designed against an ESE positioned close to the 3-end of exon
32. RT-PCR, performed in the same manner as described above,
on WT embryos treated with Z32E(133157) led to the detection
Fig. 3 Phenotype analysis of morpholino injected dmd pc2/pc2 homozygotes. (A) Although in 3-dpf-old WT larvae antibody against dystrophin locates dys-
trophin expression at the somite borders (arrowheads), (B) in dmd pc2/pc2 homozygous larvae dystrophin is not detected. (C) In contrast, homozygotes
dmd pc2/pc2 treated with Z32A(–18  7) show weak dystrophin expression and (D) homozygotes administered with a combination of Z32E(133157)
and Z32E(83107) display robust restoration of dystrophin protein at the somite borders (arrowheads). Although birefringence is evident in WT lar-
vae at 3 dpf, it is reduced in (B’) untreated and (C’) Z32A(–18  7)-injected dmd pc2/pc2 homozygotes. (D’) dmd pc2/pc2 homozygotes injected with
Z32E(133157) and Z32E(83107) demonstrate restoration of birefringence, indicating full phenotype rescue. Accordingly, haematoxylin and eosin
staining performed on cross-sections of 3-dpf-old larvae shows no phenotypic muscle in (A”) WT larvae, whereas the muscle of (B”) uninjected and (C”)
Z32A(–18  7)-treated dmdpc2/pc2 homozygous larvae is dystrophic and the phenotype is rescued in larvae (D”) administered with Z32E(133157)
and Z32E(83107). The arrow in (B”) points to mono-nucleated infiltrates and in (C”) to necrotic myofibre. The arrowhead in (C”) points to a gap where
a necrotic myofibre has been replaced by mucus. Scale bar: 50 m.
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of an additional dystrophin transcript corresponding to the dele-
tion of bp 97 to 174 of exon 32, activating a cryptic splice site
at 5-GAG gugaaa-3 (Fig. 2D, G and H). Therefore, a second mor-
pholino, Z32E(83107), was designed to target this region.
Administration of Z32E(83107) alone promotes inclusion of
the intron upstream of exon 32. However, administration of the
combined morpholinos Z32E(133157) and Z32E(83107),
in a concentration of 25 M each, induced robust skipping of tar-
geted exon 32 without non-specific morpholino effects. Similar to
the result already demonstrated with Z32A(–18  7) injection, the
proportion of the morpholino-induced transcript in relation to the
WT dystrophin transcript is significantly higher in dmd pc2/pc2
homozygotes (93%  2%) compared to WT embryos (66% 
3%; P  0.01, n  3) (Fig. 2G). Although 2 days after injection of
dmd pc2/pc2 homozygotes with the combination of
Z32E(133157) and Z32E(83107) robust skipping of exon
32 was observed, the amount of morpholino-induced dystrophin
transcript declined with progressing age of injected embryos.
However, skipping of exon 32 was still detected 21 days after
injection, suggesting that the stability of the morpholino AO 
in vivo and its efficacy in inducing exon skipping 3 weeks after
injection may provide an effective therapeutic window of treatment
(Fig. 2G).
In order to survey the effect of Z32E(133157) and
Z32E(83107) administration on dmd pc2/pc2 homozygotes,
whole mount immunohistochemistry using an antibody that rec-
ognizes zebrafish dystrophin was performed. Although dystrophin
was not detected in 3 dpf dmd pc2/pc2 homozygotes, robust dys-
trophin expression was detected in dmd pc2/pc2 homozygotes
treated with Z32E(133157) and Z32E(83107) (Fig. 3B 
and D). Accordingly, untreated dmd pc2/pc2 homozygotes display a
severely reduced muscle birefringence under polarized light,
whereas 3-dpf-old homozygotes treated with the morpholino
combination show restoration of muscle birefringence, indicative
of a full phenotypic rescue (Fig. 3B’ and D’). In addition, the mus-
cle histology of 7 dpf dmd pc2/pc2 homozygous larvae administered
with Z32E(133157) and Z32E(83107) was analysed on
cross-sections stained with haematoxylin and eosin, which con-
firmed that in contrast to untreated dmd pc2/pc2 homozygotes, no
muscle loss or enhanced fibrosis could be found 
(Fig. 3B” and D”).
Collectively, administration of two morpholinos, one against a
splice enhancer and the other blocking a cryptic splice site,
induced a high level of exon 32 skipping leading to restoration of
a robust level of dystrophin protein, sufficient to fully rescue the
phenotype of dmd pc2/pc2 homozygotes.
Determination of the threshold level of exon
skipping required to effect phenotypic rescue 
in dystrophin-deficient zebrafish
In contrast to administration of Z32E(–18  7) that only leads to
weak skipping of exons 31 and 32 and does not result in phenotype
rescue, simultaneous administration of Z32E(133157) and
Z32E(83107) shows a robust skipping effect leading to a full
phenotype rescue. We therefore surveyed in more detail the level of
skipping efficiency necessary to achieve dmd phenotype rescue.
For this purpose, we in-crossed dmd pc2/ carriers and
injected the offspring with Z32E(133157) and
Z32E(83107) combined at an equal concentration of 12 M.
First, to test the accuracy of the morpholino administration,
dmd pc2/pc2 larvae were identified by PCR and subsequently
analysed for their induced skipping effect individually. As shown
in Figure S3, the variation in the detected skipping effects was rela-
tively low. Therefore, in subsequent experiments with morpholino
concentrations varying from 0 to 12 M, two dmd pc2/pc2
homozygous larvae were combined and the proportion of exon 32
skipped transcript was analysed in relation to all dystrophin tran-
scripts by RT-PCR. Also, progression of the dystrophic pathology
after each morpholino administration was assessed by analysis of
the muscle birefringence at 3 dpf (Fig. 4). The extremes of the
injected concentrations, 0 and 12 M, resulted in a Mendelian
ratio of 24.6%  0.5% of affected larvae and no detectable dys-
trophic phenotype, respectively (data in mean  S.E.M.).
Intermediate concentrations, however, resulted in partial rescue
of the birefringence in a highly dose-dependent manner as
Fig. 4 Determination of phenotypic rescue threshold for exon-skipping
efficiency. Different concentrations of an equal mixture of Z32E
(133157) and Z32E(83107) were injected into embryos of an in-
cross of heterozygous dmd pc2/ fish. At 3 days post administration,
resulting levels of exon-skipping efficiency (blue line) were evaluated by
RT-PCR and depicted as the percentage of skipped transcript out of total
dystrophin transcript. The corresponding level of phenotypic rescue, as
evaluated by the birefringence assay, is displayed as the percentage of
larvae possessing a dystrophic phenotype from all injected larvae.
Administration of doses of combined Z32E(133157) and Z32E
(83107) below 2 M does not change the Mendalian ratio (25%) of
detected dystrophic mutants. In contrast, no larvae display a dystrophic
phenotype when injected with a concentration of 12 M and administra-
tion of intermediate concentrations lead to partial rescue as specified in
the depicted diagram. These data suggest an exon-skipping efficiency of
20–30% is required to induce effective phenotypic rescue of the highly
penetrant dystrophic phenotype evident in the zebrafish model. Data are
means  S.E.M.
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manifested by intermediate phenotype ratios. Collected data sug-
gest that a skipping efficiency of about 10% results in 10% of
detected dystrophic fish, representing a reduction of the expected
Mendalian ratio by about half. In contrast to this partial rescue, a
skipping efficiency of about 30–40% seems to result in less than
3% of injected larvae with a detectable dystrophic pathology,
revealing that a skipping efficiency of 30–40% is sufficient to
evoke a near full rescue of the dystrophic phenotype. As
described above, injection of Z32E(133157) and
Z32E(83107) into WT embryos resulted in lower exon-
skipping efficiencies. Therefore, skipping efficiencies measured
in homozygous mutants were also analysed in WT embryos.
Although exon skipping could not be detected at morpholino
concentrations of 0 M, 1 M and 2 M, injection of 12 M 
of the morpholino combination resulted in 12%  1% skipping
efficiency, 6 M in 3.5%  0.2%, 5 M in 2.8%  0.3%, 4 M
in 1.5%  0.2% and 3 M in 0.6%  0.1% 
efficiency.
Discussion
This report describes the efficacy of exon-skipping approaches in
the dystrophin-deficient zebrafish mutant dmd that accurately
resembles the severe dystrophic muscle phenotype of human
DMD. Statistical and systematic evaluation of exon-skipping effi-
ciency demonstrates that relatively robust levels of exon skipping
are required to achieve a significant level of phenotype rescue in a
severe dystrophic pathology in vivo.
Recently, two promising clinical trials employing exon
skipping of dystrophin have successfully been completed [3, 4],
but some unanswered questions remain. Amongst the problems
that have been encountered is the fact that individual AO cannot
generally be tested for side-effects in healthy volunteers, only
small biopsies can be taken that are not statistically evaluated,
and it remains unclear to which level dystrophin function needs
to be restored to significantly improve the condition of DMD
patients. Exon skipping can be surveyed in tissue culture,
however, the canine model, as well as our survey, shows a large
discrepancy in the outcome of exon-skipping experiments under-
taken in vitro and in vivo [20], pointing to the importance of
establishing rescue protocols in vivo.
Our comparison of the exon–intron structure of the human and
the zebrafish dystrophin gene shows a remarkable degree of con-
servation. With the exception of the first and the last exon, this
level of conservation enables modelling of skipping of human dys-
trophin exons in the zebrafish in vivo.
One of the novel dmd alleles that we identified in a genetic
screen, dmd pc2, carries a mutation in exon 32, deletion of which
does not disrupt the open reading frame nor results in deletion of
an essential region of the dystrophin protein. This leaves us in the
unique position of testing exon skipping in a genetically tractable
model of DMD in vivo. We have established the experimental par-
adigm that enables us to survey exon-skipping experiments in our
dmd pc2 mutant, measure the necessary skipping efficiency to res-
cue the dmd phenotype, and histologically survey the outcome of
the rescue. Our data suggest that about 10% to 20% of normal
dystrophin levels lead to only partial restoration of muscle func-
tion, whereas levels of at least 30% to 40% are needed to signifi-
cantly improve muscle function in the context of the zebrafish dys-
trophic condition. These results are comparable to studies that
correlated the level of dystrophin, quantified by antibodies, to the
severity of symptoms evident within a given patient. Although
patients with less than 10% of the normal level of dystrophin are
reported to show a severe clinical phenotype of DMD [21],
patients with 15% or less display a moderate to severe DMD phe-
notype [22] and BMD patients with mild symptoms are found to
have dystrophin levels above 30% [22, 23].
Our observations show a highly significant difference between
exon-skipping protocols performed on siblings and on mutants,
probably due to nonsense-mediated decay of mutant transcript
that harbours a premature stop-codon. This effect has to be taken
into account when skipping efficiencies in dystrophin-deficient
and WT zebrafish are compared.
Interestingly, administration of the AO Z32E(133157)
activated a cryptic splice site at 5-GAGgugaaa-3, which is highly
conserved between zebrafish and human beings. This potential
cryptic splice site should be taken into account when AO are
designed against exon 32 in human patients. It also reveals a
surprisingly high level of conservation of the genetic structure of
the dystrophin gene across a large evolutionary distance.
Furthermore, to our knowledge, this is also the first time 
two splice switching AOs, which singly either promoted intron
inclusion or activated a cryptic splice site, have been combined 
to induce robust and specific targeted exon skipping, and
suggests a new mechanistic basis to promote exon skipping of
individual exons.
The quality of life of DMD sufferers is not considered in the
dmd fish model, any treatment of DMD needs to be evaluated in
the context of individual human patients, as the use of 
exon-skipping strategies that induce less than optimal skipping
efficiency may well have a significant therapeutic benefit.
Nonetheless, these results highlight the importance of testing
exon-skipping protocols in an in vivo model that features a 
comparable mutant context to patients for which a clinical trial is
designed, in this way allowing a more accurate design and 
prediction of the clinical trial. As demonstrated here, the zebrafish
as an animal model has the advantage of rapid screening tech-
niques to generate alleles specific for exon-skipping strategies
targeting specific exons.
In summary, the dmd fish can effectively be used to evaluate
proposed therapeutic strategies for the treatment of DMD. We
reveal that exon skipping is an effective mechanism for restoring
dystrophin function in the context of a fully penetrant dystrophic
phenotype and propose that the zebrafish model will be a valuable
regent in identifying, designing and evaluating future therapeutic
strategies for DMD.
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Supporting information
Additional Supporting Information may be found in the online ver-
sion of this article:
Fig. S1 dmd allele identification. The following primer pairs
amplify the dystrophin locus, characteristic for each allele, fol-
lowed by restriction digestion with the designated enzyme.
Resulting DNA band patterns are as depicted. dmd pc1: pc1F 5-
ctgcagtctccatccaagt-3 and pc1R 5-accaagtcctggaggacct-
gagggccagggatcga-3, ClaI. dmd pc2: pc2F 5-aatgcctgtaaacaaatgt-
gtctgt-3 and pc2R 5-ccttgccatgttaacccaaa-3, BsaXI. dmd ta222a:
ta222aF 5-catacccaaggtttcaaagca-3 and ta222aR 5-
gttaagggagtgcactcgagtgaagccacgttttt-3, DraI. dmd tm90c: tm90cF
5-actgcagaacatgtataaggactccagcgctt-3 and tm90cR 5-aattac-
cttgacatctgcattttggcc-3, DdeI.
Fig. S2 Comparison of human and zebrafish dystrophin.
Numbered boxes represent exons of the human dystrophin 
isoform Dp427m with amino acid numbers indicated. The conser-
vation of each exon in comparison to the zebrafish dystrophin
sequence is written inside each box. Blue boxes represent exons
that have the same number of amino acids in human and zebrafish
and yellow ones have a different number of amino acids, as indi-
cated below each yellow box.
Fig. S3 Variation of exon skipping in individual larvae. At 3 dpf, the
exon-skipping efficiency was analysed in individual larvae admin-
istered with an equal mixture of Z32E(133157) and
Z32E(83107) at a concentration of 12 M each. The variation
in exon-skipping efficiency is relatively low, allowing pooling of
two larvae for subsequent analysis in further experiments.
Please note: Wiley-Blackwell is not responsible for the content or
functionality of any supporting materials supplied by the authors.
Any queries (other than missing material) should be directed to
the corresponding author for the article.
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